Northrop Grumman is in a sustained downtrend, with the stock declining 4.6% over the past year while the SPY gained 16.5%. The current price of $542.24 sits at 70% of its 52-week range ($479.02–$774.00), indicating it is closer to the low end and reflecting persistent selling pressure. This positioning suggests the market is pricing in fundamental headwinds, though the stock is not yet at oversold extremes. Short-term momentum shows a divergence: the 1-month return is +7.8%, while the 3-month return is -5.7%. This positive 1-month move could signal a potential short-term reversal or mean reversion, but the longer-term downtrend remains intact. The stock's beta of -0.10 is unusually low and negative, implying an inverse relationship with the market, which may be a data anomaly or reflect idiosyncratic factors. Key support is at the 52-week low of $479.02; a breakdown below this level would signal further downside. Resistance is at the 52-week high of $774.00; a breakout above that would indicate a trend reversal. The stock's low beta suggests it is less volatile than the market, but the recent sharp moves (max drawdown of -35.4%) highlight significant downside risk.

Revenue growth has been steady but decelerating. Q1 2026 revenue was $9.88 billion, up 4.4% year-over-year, but this is a slowdown from the 8.5% growth seen in Q4 2025. The largest segment, Aeronautics Systems ($3.28B), and Mission Systems ($2.86B) are key growth drivers, while Defense Systems ($1.90B) and Space Systems ($2.48B) contribute. The deceleration raises questions about the pace of future contract awards. Profitability is solid but showing margin compression. Net income for Q1 2026 was $875 million, with a net margin of 8.9%, down from 12.2% in Q4 2025. Gross margin was 19.8%, relatively stable, but operating margin fell to 10.0% from 11.9% in Q3 2025. The company remains profitable, but the declining margins warrant monitoring. The balance sheet is moderately leveraged. Debt-to-equity is 1.18, and the current ratio is 1.09, indicating adequate liquidity. Free cash flow (TTM) is $3.31 billion, but Q1 2026 saw negative FCF of -$1.82 billion due to working capital swings. ROE is a strong 25.1%, reflecting efficient capital use, but the reliance on debt (D/E 1.18) adds financial risk.